Pfizer
NEWS
South San Francisco-based Cortexyme closed on a $76 million Series B financing round.
Gilead Sciences and its development partner Galapagos NV announced positive data from its Phase II EQUATOR trial of filgotinib in psoriatic arthritis.
Over the last five years, AbbVie shares are up about 130 percent. It’s generally viewed as a volatile stock.
Pfizer’s Xalkori, the first drug approved in the United States for patients with ALK-positive and ROS1-positive non-small cell lung cancer, secured Breakthrough Therapy Designation from the U.S. Food and Drug Administration for two new indications.
After Axovant Sciences’ spectacular clinical trial failure in September 2017, the company has been reorganizing. Today it announced it had completed that reorganization by adding to its executive team and Scientific Advisory Board.
AveXis, a Novartis company based in Illinois, is investing $55 million to build a new manufacturing facility in Durham, North Carolina.
Verrica Pharmaceuticals, headquartered in West Chester, Pennsylvania, is launching an initial public offering (IPO), hoping to raise $86 million.
For investors looking for a big pharma stock, AbbVie and Pfizer are both top choices.
Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.
JOBS
IN THE PRESS